



PATENT
Attorney Docket No. 44921-5038-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Donna MENDRICK *et al.*)
Application No.: 09/917,800)
Filed: July 31, 2001)
For: MOLECULAR TOXICOLOGY MODELING)

Group Art Unit: 1631
Examiner: Mr. Cheyne Ly

#15
Plunkett
5/27/03

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

APR 30 2003

Sir:

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. These documents were received in Applicants' corresponding International Application No. PCT/US01/23872, filed on July 31, 2001.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies a document as "prior art" against any claim in the application and Applicants determine that the cited document does not constitute "prior art"

under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,
MORGAN, LEWIS & BOCKIUS LLP



Michael S. Tuscan
Reg. No. 43,210

Dated: **April 29, 2003**

Customer No. 009629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Ave., N.W.
Washington, D.C. 20004
Tel: 202-739-3000
Fax: 202-739-3001

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449				Atty. Docket No. 44921-5038-US		Application No. 09/917,800	
				Applicants: Donna L. MENDRICK <i>et al.</i>		Page 1 of 1	
				Filing Date: July 31, 2001		Group Art Unit: 1631	

U.S. PATENT DOCUMENTS							
Document No.	Date	Name	Class	Sub-Class	Filing Date		

FOREIGN PATENT DOCUMENTS							
Document No.	Date	Country	Class	Sub-Class	Translation		
WO 00/12760	2000-03-09	WO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
	Bissig <i>et al.</i> , "Functional expression cloning of the canalicular sulfate transport system of rat hepatocytes," <i>J Biol Chem</i> 269(4):3017-3021, 1994.
	GenBank Accession No. L23413, Bissig <i>et al.</i> , "Rattus norvegicus sulfate anion transporter (sat-1) mRNA," April 12, 1994.
	Farr <i>et al.</i> , "Concise review: gene expression applied to toxicology," <i>Toxicol Sci</i> 50(1):1-9, 1999.
	Nuwaisyr <i>et al.</i> , "Microarrays and toxicology: the advent of toxicogenomics," <i>Molecular Carcinogenesis</i> 24(3): 153-159, 1999.
	Raburn <i>et al.</i> , "Stage-specific expression of B Cell Translocation Gene 1 in rat testis," <i>Endocrinology</i> 136(12): 5769-5777, 1995.
	GenBank Accession No. L26268, Raburn <i>et al.</i> , "Rattus norvegicus anti-proliferative factor (BTG1) mRNA," January 26, 1996
	International Search Report in Applicants' PCT Application No. PCT/US01/23872, March 21, 2003.

RECEIVED

APR 30 2003

TECH CENTER 1600/2900

Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	